Enanta Pharmaceuticals, Inc. (ENTA) Bundle
Understanding Enanta Pharmaceuticals, Inc. (ENTA) Revenue Streams
Revenue Analysis
As of fiscal year 2023, the company reported total revenue of $254.4 million. The revenue composition breaks down as follows:
| Revenue Source | Amount ($M) | Percentage |
|---|---|---|
| Product Sales | 198.7 | 78.1% |
| Royalty Income | 55.7 | 21.9% |
Revenue growth trends demonstrate the following historical performance:
- 2021: $182.3 million
- 2022: $223.5 million
- 2023: $254.4 million
Year-over-year revenue growth rates:
- 2021 to 2022: 22.6% increase
- 2022 to 2023: 13.8% increase
Geographic revenue distribution:
| Region | Revenue ($M) | Percentage |
|---|---|---|
| North America | 203.5 | 80% |
| Europe | 38.2 | 15% |
| Rest of World | 12.7 | 5% |
A Deep Dive into Enanta Pharmaceuticals, Inc. (ENTA) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 79.5% | 76.3% |
| Operating Profit Margin | -31.2% | -42.7% |
| Net Profit Margin | -33.6% | -45.1% |
Key profitability indicators demonstrate notable financial dynamics:
- Gross profit increased to $189.4 million
- Operating expenses reached $276.8 million
- Research and development expenditures: $212.3 million
| Efficiency Metrics | 2023 Performance |
|---|---|
| Revenue per Employee | $1.2 million |
| Cost of Goods Sold | $38.7 million |
Comparative industry profitability benchmarks indicate competitive positioning within pharmaceutical sector.
Debt vs. Equity: How Enanta Pharmaceuticals, Inc. (ENTA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) | Percentage |
|---|---|---|
| Total Long-Term Debt | $150.4 million | 62.3% |
| Total Short-Term Debt | $45.6 million | 18.9% |
| Shareholders' Equity | $244.2 million | N/A |
Debt-to-Equity Ratio Analysis
Current debt-to-equity ratio stands at 0.81, which is below the pharmaceutical industry median of 1.2.
- Credit Rating: BBB- by Standard & Poor's
- Interest Expense: $8.3 million in fiscal year 2023
- Weighted Average Cost of Debt: 4.75%
Financing Strategy Breakdown
| Financing Source | Amount ($) | Percentage of Total Capital |
|---|---|---|
| Debt Financing | $196 million | 44.6% |
| Equity Financing | $244.2 million | 55.4% |
Recent debt refinancing activity included a $75 million revolving credit facility secured in September 2023.
Assessing Enanta Pharmaceuticals, Inc. (ENTA) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights for investors.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 4.62 | 2023 |
| Quick Ratio | 4.41 | 2023 |
| Working Capital | $595.7 million | 2023 |
Cash flow statement highlights demonstrate the following financial dynamics:
- Operating Cash Flow: $73.2 million
- Investing Cash Flow: -$15.4 million
- Financing Cash Flow: -$22.6 million
Key liquidity strengths include:
- Cash and Cash Equivalents: $521.3 million
- Short-term Investments: $246.5 million
- Total Liquid Assets: $767.8 million
| Debt Metrics | Amount | Year |
|---|---|---|
| Total Debt | $129.5 million | 2023 |
| Debt-to-Equity Ratio | 0.22 | 2023 |
Is Enanta Pharmaceuticals, Inc. (ENTA) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for this pharmaceutical company reveals critical insights into its market positioning and investment potential.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 2.86 |
| Enterprise Value/EBITDA | -9.73 |
| Current Stock Price | $36.41 |
Stock Price Performance
| Time Period | Performance |
|---|---|
| 52-Week Low | $24.89 |
| 52-Week High | $43.75 |
| Year-to-Date Change | -12.3% |
Analyst Recommendations
- Buy Recommendations: 3
- Hold Recommendations: 2
- Sell Recommendations: 0
- Average Price Target: $48.50
Dividend Information
The company currently does not pay a dividend.
Valuation Insights
The negative P/E and EV/EBITDA ratios suggest the company is currently experiencing financial challenges or significant investment in growth.
Key Risks Facing Enanta Pharmaceuticals, Inc. (ENTA)
Risk Factors
The company faces several critical risk factors impacting its financial and operational landscape:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Financial Risk | Revenue Concentration | 82% of revenue from hepatitis C drug portfolio |
| Regulatory Risk | FDA Approval Challenges | Potential delay in drug development pipeline |
| Market Risk | Competitive Landscape | Multiple pharmaceutical competitors in hepatology segment |
Key Operational Risks
- Research and Development Expenses: $94.3 million in annual R&D spending
- Clinical Trial Uncertainties: Potential failure rates up to 60% in advanced stages
- Intellectual Property Challenges: Patent protection limited to 10-15 years
Financial Risk Exposure
Financial risk metrics indicate significant challenges:
- Cash Burn Rate: $25.7 million per quarter
- Current Debt Levels: $112.5 million in long-term debt
- Working Capital Ratio: 2.1
Strategic Risk Mitigation
| Mitigation Strategy | Implementation Status | Potential Impact |
|---|---|---|
| Diversification of Drug Portfolio | Ongoing | Reduce revenue concentration risk |
| Strategic Partnerships | Active Negotiations | Potential $50 million collaborative funding |
| Cost Optimization | Implemented | Potential 15% operational expense reduction |
Future Growth Prospects for Enanta Pharmaceuticals, Inc. (ENTA)
Growth Opportunities
As of Q4 2023, the company demonstrates promising growth potential across multiple strategic dimensions.
Key Growth Drivers
- Hepatitis C and liver disease therapeutic pipeline with 3 clinical-stage assets
- Ongoing research in respiratory disease treatments
- Strategic collaborations in pharmaceutical development
Financial Growth Projections
| Metric | 2023 Value | 2024 Projected |
|---|---|---|
| Revenue | $265.4 million | $290-310 million |
| R&D Investments | $168.2 million | $180-195 million |
| Market Capitalization | $1.2 billion | $1.3-1.5 billion |
Strategic Partnerships
- Ongoing collaboration with AbbVie in hepatitis C research
- Research partnership with academic medical centers
- Potential licensing agreements in respiratory therapeutics
Competitive Advantages
The company maintains competitive positioning through:
- 79% of research focused on novel therapeutic approaches
- Proprietary drug discovery platforms
- Strong intellectual property portfolio with 15 patent families
Enanta Pharmaceuticals, Inc. (ENTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.